J. Keith Joung is a leading innovator in the field of genome editing. He is currently Pathologist, an MGH Research Scholar, and Associate Chief of Pathology for Research at Massachusetts General Hospital (MGH) as well as Professor of Pathology at Harvard Medical School. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH. Dr. Joung has been a pioneer in the development of engineered zinc finger, transcription activator-like effector (TALE), and CRISPR-Cas technologies and their applications for targeted genome editing and epigenome editing of human cells. He has received numerous awards including an NIH Director's Pioneer Award, an NIH Director's Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery and Transposagen Biopharmaceuticals. He is also a scientific co-founder of Editas Medicine, a company dedicated to the translation of genome editing technologies for therapy of human diseases.
Dr. Joung holds a PhD in genetics from Harvard University, an MD from Harvard Medical School, and an AB in biochemical sciences from Harvard College.